📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

Published 03/28/2019, 05:45 AM
Updated 07/09/2023, 06:31 AM
US500
-
DJI
-

Tandem Diabetes (TNDM) closed the most recent trading day at $63.76, moving +1.21% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.36%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.34%.

Coming into today, shares of the insulin pump maker had gained 1.84% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 gained 0.64%.

Investors will be hoping for strength from TNDM as it approaches its next earnings release. In that report, analysts expect TNDM to post earnings of -$0.28 per share. This would mark year-over-year growth of 72.82%. Meanwhile, our latest consensus estimate is calling for revenue of $50.32 million, up 84.44% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.72 per share and revenue of $264.27 million, which would represent changes of +71.76% and +43.73%, respectively, from the prior year.

Any recent changes to analyst estimates for TNDM should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.15% higher within the past month. TNDM is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.



Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.